Traws Pharma, Inc. (TRAW)
- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $0.23
- As of
Kresmion compiles this page from TRAW's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
Traws Pharma, Inc. (TRAW): no institutional manager tracked by Kresmion reported a non-option position in the latest Form 13F reporting quarter, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-11-16.
See the full TRAW dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for TRAW on one page. Preview it with sample data, then open it live with a free account.
Preview the TRAW dossierActive events for TRAW
- mediumEarnings above estimates
Q2-2026: Beat consensus by 26.9%, EPS $-0.25 vs $-0.3422 estimate
- mediumEarnings above estimates
Q4-2024: Beat consensus by 1082.0% - EPS $95.66 vs $-9.741 estimate
- mediumEarnings below estimates
Q3-2024: Missed consensus by 41.0% - EPS $-8.81 vs $-6.2475 estimate
- mediumEarnings above estimates
Beat consensus by 1082.0% - EPS $95.66 vs $-9.741 estimate
- mediumEarnings above estimates
Q4-2025: Beat consensus by 150.5% - EPS $0.63 vs $-1.2485 estimate
FREE, NO ACCOUNT
Every event on TRAW, as it fires
You are seeing 5 of 6 events recorded on TRAW since 2026-05-24.
The five above landed across 3 days. The other 1 were recorded on those same days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
No non-option holdings from tracked managers in this reporting quarter. Other reporting quarters are linked above.
Recent SEC filings, TRAW
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
More data on TRAW
TRAW against its peers
TRAW's operating margin of -640.7% ranks in the 58th percentile of 5 Biotechnology sub-industry peers, fiscal periods ending between 2025-03-31 and 2026-04-30.
| Metric | TRAW | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 2.8M USD | 10898 USD | 94 | 8 |
| Gross margin | n/a | 82.5% | n/a | 5 |
| Operating margin | -640.7% | -1601.2% | 58 | 5 |
| Net margin | 328.7% | -2419.9% | 92 | 5 |
| Return on equity | n/a | -121.5% | n/a | 13 |
| P / E | 0.3x | n/a | n/a | 0 |
| 1 year | -87.9% | -89.0% | 50 | 12 |
Peers (19): ABPO, BCAB, CVKD, VSBC, KALA, DRMA, MBIO, ERNA, PMCB, EOCN, SILO, NCNA, JUNS, CMND, GRI, LSBCF.D, AAGH, DCOY, APTOF.D. Left out: LIMN (no annual filing), NRSN (no annual filing), BVAXF (no annual filing), XTLB (period gap), LIANY (no annual filing), VCNX (period gap). Fiscal periods ending between 2025-03-31 and 2026-04-30. Every figure is one full fiscal year read from one annual filing (TRAW: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Cite this data
Kresmion counts the managers it follows that reported a non-option position in TRAW on Form 13F-HR for the latest reporting quarter, orders those positions by the value each filing reports, and lists the company's latest SEC filings and the events Kresmion recorded on TRAW in the last 180 days.
Upstream: SEC EDGAR filings for TRAW
Kresmion, "Traws Pharma, Inc. (TRAW) institutional holdings and SEC filings", data as of 2026-11-16, https://kresmion.com/research/TRAW. Upstream data: SEC EDGAR filings for TRAW.
Link to this data (HTML):
<a href="https://kresmion.com/research/TRAW">Traws Pharma, Inc. (TRAW) institutional holdings and SEC filings (Kresmion)</a>
Writing about this? Press contact and ready-to-quote figures
Follow TRAW on a live board
Kresmion is a source-first market terminal for cross-asset market intelligence. Open a board scoped to TRAW for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.